Sep 10, 2026, 12:15 UTC
Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
Source:Jun 2, 2026, 00:00 UTC
Oncolytics Biotech Inc. appointed Stephen Glover as a director, with an option to purchase 96,000 shares vesting over three years.
Jun 2, 2026, 00:00 UTC
Oncolytics Biotech Inc. appointed John McAdory as Chief Operating Officer, effective June 1, 2026.